Amidst a devastating outbreak, scientists and doctors in the Democratic Republic of Congo have been running clinical trials on experimental Ebola treatments. Now, they have been successful. While an experimental vaccine had been providing protection from catching the virus, the new treatments are groundbreaking for people who are already infected.

New monoclonal antibody treatments were able to lower death rates to as low as 11% for those treated soon after being infected. With this good news and success there is still a lot to be done, however, in terms of containing the Ebola epidemic.

Therefore this should be cialis online cheapest used to avail relief from the cardiovascular dysfunctions. Sexual disorders ruin a person s life completely and become able to handle sorrow, super active tadalafil fears and damages patiently. Kamagra is available in packets wholesale cialis pills containing total 100mg tablets. If such a situation continues for long, it might even lead to the check for info generico levitra on line breakdown of a relationship or marriage failed.

With the WHO’s announcement a new trial will now kick off, directly comparing Regeneron to mAb114, which is being produced by a Florida-based company called Ridgeback Biotherapeutics. And all Ebola treatment units in the outbreak zone will now only administer the two most effective monoclonal antibody drugs, according to the WHO’s director of health emergencies, Mike Ryan.

“Today’s news puts us one more step to saving more lives,” said Ryan. “The success is clear. But there’s also a tragedy linked to the success. The tragedy is that not enough people are being treated. We are still seeing too many people staying away from treatment centers, people not being found in time to benefit from these therapies.”